Voriconazole Intravenous (Iv) Solution Suppliers & Bulk Manufacturers
Available Forms: Intravenous (IV) Solution
Available Strengths: 200 mg/100 mL
Reference Brands: Vfend(US & EU)
Category: Anti-fungal
Voriconazole IV inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis essential for fungal cell membranes. It provides broad-spectrum antifungal activity, rapid systemic treatment, and excellent tissue penetration. Benefits include high efficacy against invasive fungi like Aspergillus, making it vital for treating severe fungal infections. Voriconazole Intravenous (IV) Solution is available in Intravenous (IV) Solution and strengths such as 200 mg/100 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Voriconazole Intravenous (IV) Solution is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Voriconazole Intravenous (IV) Solution can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Voriconazole IV solution is approved in the EU and US for severe fungal infections. In the EU, Pfizer’s Vfend IV is regulated by EMA, backed by dossiers demonstrating safety, efficacy, and quality. In the US, FDA approval is based on comprehensive clinical data, biosimilarity assessments, and ongoing pharmacovigilance. Both regions require detailed regulatory dossiers for initial approval and continuous safety monitoring. For expert assistance with regulatory dossiers, submissions, and compliance, visit PharmaTradz, your trusted partner in pharmaceutical regulatory solutions. We support efficient market access for voriconazole IV formulations, ensuring adherence to European and American standards for safe, effective antifungal therapy.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Voriconazole is used to treat serious fungal infections, particularly invasive aspergillosis, candidemia, esophageal candidiasis, and infections caused by Scedosporium and Fusarium species. It is often prescribed for immunocompromised patients and is known for its broad-spectrum antifungal activity and strong efficacy.
Voriconazole contains the active triazole antifungal compound voriconazole. It is formulated with suitable pharmaceutical excipients designed to enhance absorption, stability, and bioavailability depending on the dosage form.
The main trade name for voriconazole is Vfend, widely marketed in the USA, EU, UK, and other global regions.
Vfend is manufactured by Pfizer. Generic versions of voriconazole are also produced by several GMP-certified manufacturers across different international markets.
The generic name is voriconazole.
The primary brand name is Vfend.
Voriconazole is manufactured in Pfizer’s regulated facilities in the USA and Europe, along with multiple GMP-approved pharmaceutical companies that produce generic voriconazole for global supply.
Related Products
Naftifine Hydrochloride
Strength:
1 %, 2%
Form: Cream / Gel
Reference Brands: Naftin (USA), Xolafin (USA)
View Details
Sertaconazole Nitrate
Strength:
2 %
Form: Creams
Reference Brands: Ertaczo (USA), Zalain (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
